Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Pan American Silver generated $344 million in attributable free cash flow for Q2 2026, driven by strong silver production at La Colorada and Juanicipio.
NurExone signed a binding MOU with Made Scientific for exclusive U.S. GMP manufacturing and commercial supply of exosome therapies, targeting first batches in H1 2027.
Reviva filed a U.S. composition of matter patent application for a new form of brilaroxazine, seeking accelerated review to extend commercial exclusivity through 2046.
